Randomized trial of bevacizumab in advanced renal cell carcinoma

被引：0
|
作者：
Ronald M. Bukowski
机构：
来源：
Current Oncology Reports | 2008年 / 10卷
关键词：
Renal Cell Carcinoma; Bevacizumab; Clin Oncol; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：99 / 100
页数：1
相关论文
共 50 条
  • [31] Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial
    Gruenwald, V.
    Cella, D.
    Escudier, B. J.
    Hammers, H. J.
    George, S.
    Nathan, P.
    Grimm, M. -O.
    Rini, B. I.
    Doan, J.
    Ivanescu, C.
    Paty, J.
    Mekan, S.
    Motzer, R. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 42 - 42
  • [32] RECOMBINANT LEUKOCYTE INTERFERON ALPHA-2A AND MEDROXYPROGESTERONE IN ADVANCED RENAL-CELL CARCINOMA - A RANDOMIZED TRIAL
    STEINECK, G
    STRANDER, H
    CARBIN, BE
    BORGSTROM, E
    WALLIN, L
    ACHTNICH, U
    ARVIDSSON, A
    SODERLUND, V
    NASLUND, I
    ESPOSTI, PL
    NORELL, SE
    ACTA ONCOLOGICA, 1990, 29 (02) : 155 - 162
  • [33] Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma:: A randomized phase III clinical trial
    Ravaud, Alain
    Hawkins, Robert
    Gardner, Jason P.
    von der Maase, Hans
    Zantl, Niko
    Harper, Peter
    Rolland, Frederic
    Audhuy, Bruno
    Machiels, Jean-Pascal
    Petavy, Frank
    Gore, Martin
    Schoffski, Patrick
    El-Hariry, Iman
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2285 - 2291
  • [34] Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
    Bukowski, R. M.
    Eisen, T.
    Szczylik, C.
    Stadler, W. M.
    Simantov, R.
    Shan, M.
    Elting, J.
    Pena, C.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2011, 185 (03): : 808 - 808
  • [36] Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
    Choueiri, T.
    Escudier, B.
    Powles, T.
    Mainwaring, P.
    Rini, B.
    Donskov, F.
    Hammers, H.
    Hutson, T.
    Roth, B.
    Peltola, K.
    Lee, J. L.
    Heng, D.
    Schmidinger, M.
    Borgman-Hagey, A.
    Hessel, C.
    Scheffold, C.
    Schwab, G.
    Tannir, N.
    Motzer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S709
  • [37] A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
    Voss, Martin H.
    Bhatt, Rupal S.
    Vogelzang, Nicholas J.
    Fishman, Mayer
    Alter, Robert S.
    Rini, Brian, I
    Beck, J. Thaddeus
    Joshi, Monika
    Hauke, Ralph
    Atkins, Michael B.
    Burgess, Earle
    Logan, Theodore F.
    Shaffer, David
    Parikh, Rahul
    Moazzam, Nauman
    Zhang, Xiaosha
    Glasser, Chad
    Sherman, Matthew L.
    Plimack, Elizabeth R.
    CANCER, 2019, 125 (14) : 2400 - 2408
  • [38] Phase II ECOG trial of atrasentan in advanced renal cell carcinoma
    Manola, J.
    Carducci, M.
    Nair, S.
    Liu, G.
    Rousey, S.
    Wilding, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Phase II trial of bortezomib for patients with advanced renal cell carcinoma
    Kondagunta, GV
    Drucker, B
    Schwartz, L
    Bacik, J
    Marion, S
    Russo, P
    Mazumdar, M
    Motzer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3720 - 3725
  • [40] Phase II trial of thalidomide for patients with advanced renal cell carcinoma
    Motzer, RJ
    Berg, W
    Ginsberg, M
    Russo, P
    Vuky, J
    Yu, R
    Bacik, J
    Mazumdar, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 302 - 306
12345